Fecal Microbiota Transplantation

Borody, Thomas J.; Campbell, John

doi:10.1016/j.gtc.2012.08.008

Cited by 114 publications

(54 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Previously published data suggest higher success rates of FMT via colonoscopy compared to other methods. 11,16,17,19 However, newer technologies such as fecal transplant capsules may have comparable success rates of FMT for RCDI. 42 If the capsule method is indeed equivocal, alternative routes for FMT may prove even less costly than the values used in this model, with a presumed similar safety profile.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 Though no randomized controlled trials have been conducted to determine the efficacy of FMT in treating RCDI, the sparse published literature on this new technique suggests favorable cure rates with FMT, with what appears to be a relatively low risk of associated adverse events. 5,10,11,[13][14][15][16][17][18][19] One recent economic analysis demonstrated FMT to be cost-effective in the context of RCDI. 20 The purpose of this study was to estimate the cost-effectiveness of FMT compared with vancomycin for the treatment of RCDI in adults, specifically following guidelines proposed by the ACG and AGA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Varier

Biltaji

Smith

et al. 2015

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Varier

Biltaji

Smith

et al. 2015

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

“…Fecal microbiota transplantation (FMT) is a procedure in which large amounts of intestinal microbiota from prescreened healthy donors are transplanted to the gastrointestinal tract of recipients to help redress intestinal dysbacteriosis in patients and reconstitute functional intestinal microecology (Borody and Campbell, 2012; de Groot et al, 2017). Previous studies have demonstrated that FMT has achieved favorable results in the treatment of clostridium difficile infection (CDI) and inflammatory bowel disease (IBD) (Cammarota et al, 2014; Wang et al, 2016; Ma et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Fecal Microbiota Transplantation Ameliorates Experimentally Induced Colitis in Mice by Upregulating AhR

et al. 2018

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic non-specific inflammatory disease that occurs in the colon and rectum. While fecal microbiota transplantation (FMT) is gaining attention as a clinical treatment of UC, the molecular mechanisms behind this effect have yet to be fully understood. A C57BL/6 mouse model was established to test whether FMT promotes the recovery of colon inflammation. Administration of 2% dextran sulfate sodium (DSS) for 7 days successfully induced acute colitis, as evidenced by diarrhea, hematochezia and colon shortening as well as a decrease in body weight. FMT alleviated the severity of colon mucosa injury and improved histological alterations compared with that of the DSS group. In addition, FMT promoted homeostasis of the intestinal microbiota. Furthermore, FMT upregulated the expression of aryl hydrocarbon receptor (AHR), interleukin-10 (IL-10), and transforming growth factor beta (TGF-β) in colon tissues. These results suggest that the significant anti-inflammatory effect of FMT may be attributed to its promotion of IL-10 and TGF-β production and AHR activation. Based on these results, FMT had a favorable therapeutic effect on DSS-induced colitis.

show abstract

“…Though previously published data suggest higher success rates of FMT via colonoscopy compared with other methods, newer technologies, such as faecal transplant capsules or using frozen inoculum, may have comparable success rates of FMT for RCDI [15,20,21,23,55,56]. If the capsule method, or another, is indeed equivocal, alternative routes for FMT may prove even less costly than the values used in this model, with a presumed similar safety profile.…”

Section: Discussionmentioning

confidence: 75%

“…While an enema is a common transplantation method, alternative routes include nasoenteral (nasogastric or nasojejunal) tubes and colonoscopy [15,16]. Though no randomized controlled trials have been conducted to determine the efficacy of FMT in treating RCDI, the sparse published literature on this new technique suggests that rates of cure with FMT are favourable, with minimal adverse effects [5,14,15,[17][18][19][20][21][22][23]. In addition, one recent economic analysis demonstrated FMT as cost-effective in the context of RCDI [24].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection

Varier

Biltaji

Smith

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Clostridium difficile infection (CDI) is costly. Current guidelines recommend metronidazole as first-line therapy and vancomycin as an alternative. Recurrence is common. Faecal microbiota transplantation (FMT) is an effective therapy for recurrent CDI (RCDI). This study explores the cost-effectiveness of FMT, vancomycin and metronidazole for initial CDI. We constructed a decision-analytic computer simulation using inputs from published literature to compare FMT with a 10-14-day course of oral metronidazole or vancomycin for initial CDI. Parameters included cure rates (baseline value (range)) for metronidazole (80% (65-85%)), vancomycin (90% (88-92%)) and FMT(91% (83-100%)). Direct costs of metronidazole, vancomycin and FMT, adjusted to 2011 dollars, were $57 ($43-72), $1347 ($1195-1499) and $1086 ($815-1358), respectively. Our effectiveness measure was quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted from the third-party payer perspective. Analysis using baseline values showed that FMT($1669, 0.242 QALYs) dominated (i.e. was less costly and more effective) vancomycin ($1890, 0.241 QALYs). FMT was more costly and more effective than metronidazole ($1167, 0.238 QALYs), yielding an incremental cost-effectiveness ratio (ICER) of $124 964/QALY. One-way sensitivity analyses showed that metronidazole dominated both strategies if its probability of cure were >90%; FMT dominated if it cost <$584. In a probabilistic sensitivity analysis at a willingness-to-pay threshold of $100 000/QALY, metronidazole was favoured in 55% of model iterations; FMT was favoured in 38%. Metronidazole, as the first-line treatment for CDIs, is less costly. FMT and vancomycin are more effective. However, FMT is less likely to be economically favourable, and vancomycin is unlikely to be favourable as first-line therapy when compared with FMT.

show abstract

Fecal Microbiota Transplantation

Cited by 114 publications

References 71 publications

Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Fecal Microbiota Transplantation Ameliorates Experimentally Induced Colitis in Mice by Upregulating AhR

Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection

Contact Info

Product

Resources

About